|Bid||50.21 x 1100|
|Ask||50.20 x 800|
|Day's Range||48.88 - 50.97|
|52 Week Range||41.63 - 99.82|
|Beta (3Y Monthly)||2.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||84.13|
Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 15) Applied Therapeutics Inc (NASDAQ: APLT ) (debuted on ...
Although it is rapidly approaching 13F season and traders are closely watching oil stocks due to the rising Middle East tensions, several stocks such as Alibaba Group Holding Limited (NYSE:BABA), Altaba Inc. (NASDAQ:AABA), Cisco Systems, Inc. (NASDAQ:CSCO), Agios Pharmaceuticals Inc (NASDAQ:AGIO), and Virtusa Corporation (NASDAQ:VRTU) are in the spotlight for various reasons. Let's analyze why traders are watching each stock […]
Shares of Cisco Systems CSCO rose more than 2.5% in extended trading Wednesday after the networking hardware company reported better-than-expected fourth quarter results. The company also gave strong guidance for the fourth quarter with estimated earnings per share and revenue both coming in higher than Refinitiv consensus estimates. Farfetch reported a loss of 22 cents per share, worse than the expected loss of 16 cents per share, and revenue of $174.1 million, higher than the expected $171.1 million, according to Refinitiv consensus estimates.
CAMBRIDGE, Mass., May 15, 2019 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today.
– TIBSOVO® Demonstrated a Statistically Significant Improvement in Progression-Free Survival Compared to Placebo – – Safety Profile Consistent with Published Phase 1 Data in.
Agios Pharmaceuticals Inc NASDAQ/NGS:AGIOView full report here! Summary * Bearish sentiment is moderate and declining Bearish sentimentShort interest | NeutralShort interest is moderately high for AGIO with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on May 10. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $3.59 billion over the last one-month into ETFs that hold AGIO are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Agios (AGIO) benefits from earnings as well as revenue beat in first-quarter 2019. However, Tibsovo sales fall sequentially, pulling the stock down.
– TIBSOVO® is the First and Only Therapy Approved for Newly Diagnosed AML Patients with an IDH1 Mutation who are Ineligible for Intensive Chemotherapy – – sNDA Approval Based.
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 8.62% and 38.64%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Cambridge, Massachusetts-based company said it had a loss of $1.59 per share. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...
Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today reported business highlights and financial results for the first quarter ended March 31, 2019. “We made progress on expansion opportunities for TIBSOVO® across the frontline AML setting. FDA accepted our sNDA in newly diagnosed AML, the HOVON/AMLSG Phase 3 intensive chemotherapy combination study initiated, and we received Breakthrough Therapy Designation for the combination of TIBSOVO® and azacitadine.
NEW YORK, NY / ACCESSWIRE / May 2, 2019 / Agios Pharmaceuticals, Inc. (NASDAQ: AGIO ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 2, 2019 at 8:00 AM ...
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the fourth quarter, which unveil their equity positions as of December 31. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, May 2, 2019 at 8:00 a.m. ET to report its first quarter 2019 financial results and other business highlights. A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism and adjacent areas of biology.
Agios Pharmaceuticals, Inc.'s (NASDAQ:AGIO) released its most recent earnings update in December 2018, which showed that losses became smaller relative to the prior year's level - great news for inve...
Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced two newly created commercial leadership roles to support the commercialization of the company’s medicines in the United States and Europe. Darrin Miles, who has been with the company since 2015, most recently as vice president, oncology program leadership, has been promoted to senior vice president, U.S. commercial and global marketing and will be responsible for leading the commercial organization in the U.S. and driving coordinated marketing efforts worldwide for all of Agios products and development candidates.
AVEO Oncology (AVEO) reports positive results from phase Ib study of ficlatuzumab in combination with cytarabine in patients with relapsed and refractory acute myeloid leukemia.
Agios' (AGIO) first wholly owned precision medicine, Tibsovo, has been picking up the sales pace since its FDA approval last year with strong sequential growth delivered in Q4.
Agios (AGIO) receives a Breakthrough Therapy designation for Tibsovo combo to treat the newly diagnosed acute myeloid leukemia in adult patients with an IDH1 mutation.